Last Updated: November 16, 2026

TAUVID Drug Patent Profile

« Back to Dashboard


When do Tauvid patents expire, and what generic alternatives are available?

Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Tauvid

Tauvid was eligible for patent challenges on May 28, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for TAUVID?
  • What are the global sales for TAUVID?
  • What is Average Wholesale Price for TAUVID?
Summary for TAUVID
US Patents:1
Applicants:1
NDAs:1

US Patents and Regulatory Information for TAUVID

TAUVID is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAUVID is ⤷  Start Trial.

This potential generic entry date is based on patent 8,932,557.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 DISCN Yes No 8,932,557 ⤷  Start Trial Y ⤷  Start Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-004 Jul 1, 2022 RX Yes Yes 8,932,557 ⤷  Start Trial Y ⤷  Start Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 DISCN Yes No 8,932,557 ⤷  Start Trial Y ⤷  Start Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-003 Jul 1, 2022 RX Yes Yes 8,932,557 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TAUVID

When does loss-of-exclusivity occur for TAUVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12381042
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 15390
Estimated Expiration: ⤷  Start Trial

Patent: 73963
Estimated Expiration: ⤷  Start Trial

China

Patent: 4781234
Estimated Expiration: ⤷  Start Trial

Patent: 7011342
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 31359
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0220401
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 25258
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 47558
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 47558
Estimated Expiration: ⤷  Start Trial

Patent: 99763
Estimated Expiration: ⤷  Start Trial

Patent: 52572
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 47558
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 58352
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 76206
Estimated Expiration: ⤷  Start Trial

Patent: 11512354
Estimated Expiration: ⤷  Start Trial

Patent: 15517572
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 47558
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 47558
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 47558
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 47558
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1609504
Estimated Expiration: ⤷  Start Trial

Patent: 100135235
Estimated Expiration: ⤷  Start Trial

Patent: 150002854
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 92830
Estimated Expiration: ⤷  Start Trial

Patent: 07992
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAUVID around the world.

Country Patent Number Title Estimated Expiration
Australia 2012381042 ⤷  Start Trial
Canada 2715390 ⤷  Start Trial
Canada 2873963 ⤷  Start Trial
China 104781234 ⤷  Start Trial
China 107011342 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

TAUVID (delayed-release amifampridine) investment scenario and fundamentals analysis

Last updated: July 30, 2026

TAUVID is an orphan-designated, late-stage neuromuscular drug in the neuromuscular/rare-disease market for Lambert-Eaton myasthenic syndrome (LEMS). A business model built on exclusivity plus payer access is the core value driver, with the main risk centered on (1) durability of pricing and reimbursement in LEMS, (2) competitive pressure from symptomatic agents and next-generation amifampridine delivery concepts, and (3) patent and regulatory entry barriers that determine generic or alternative formulation timing.

Bottom line: TAUVID’s investability hinges on margin sustainability in a small addressable population and on whether the IP stack meaningfully constrains “work-alike” products or generic amifampridine entry. Without confirmed patent and FDA exclusivity timelines for TAUVID’s specific dosage form and any Orange Book listings, the investment scenario cannot be sized with defensible date-based risk modeling.

What is TAUVID and how is it regulated in the US (FDA status, approval pathway, Orange Book listings)?

TAUVID is amifampridine delayed-release therapy for Lambert-Eaton myasthenic syndrome (LEMS).

Regulatory status and FDA entry points

  • For investment-grade modeling, TAUVID value depends on:
    1. whether TAUVID is listed in the FDA Orange Book (with patent numbers and expiration dates),
    2. whether any product-specific exclusivities apply (e.g., orphan drug exclusivity, if applicable),
    3. whether any supplemental approvals introduced new patents tied to the delayed-release formulation or manufacturing.

Featured-snippet answer (what to verify for Orange Book-driven exclusivity)

  • The Orange Book is the single source to map:
    • Drug product patent coverage (listed formulation and composition)
    • Method patents (if any are listed to cover use or manufacture)
    • Patent expiration dates and any “use-based” exclusivity blocks

Investment implication

  • If TAUVID is not Orange Book-listed with granular delayed-release patents, alternative products and generic entry risk rises materially.
  • If it is listed with multiple product and method-of-use patents, litigation or settlement risk becomes a key valuation input for the base case.

What patents protect TAUVID and what is the patent expiration timeline?

A complete TAUVID patent estate review requires the specific Orange Book patent numbers, their filing/expiration, and whether there are continuation families or new formulation patents tied to delayed-release coverage.

Featured-snippet answer

  • The patent-expiration timeline for TAUVID must be anchored to:
    • Orange Book listed patents for the marketed delayed-release product
    • Any related published applications in the same families
    • Any known litigation affecting exclusivity or enforceability

Investment implication

  • For small rare-disease franchises, a single near-term composition-of-matter or formulation patent can define the whole investment curve.
  • If the estate is dominated by narrow formulation claims (e.g., specific release profiles, excipient systems, or manufacturing steps), the commercial risk shifts from “generic launch” to “work-around formulation” entry.

When does TAUVID lose exclusivity (orphan drug exclusivity, patent expiry, and other blocking periods)?

Loss of exclusivity must be modeled along two timelines:

  1. Patent expiry (hard dates)
  2. Regulatory exclusivity (hard and soft blockers)

Key exclusivity categories to model

  • Orphan drug exclusivity (if granted to the specific TAUVID indication)
  • Patent term adjustments and orphan-related exclusivity extensions (if applicable)
  • 505(b)(2) or ANDA pathways that may rely on listed patents and trigger Paragraph IV

Featured-snippet answer

  • Exclusivity modeling requires the exact Orange Book list of TAUVID patents and their associated exclusivity determinations. Without those identifiers, any date-based claim would be non-actionable.

How strong is the patent estate for TAUVID versus generic and “work-alike” delayed-release amifampridine products?

In investment practice, TAUVID’s competitive shield has to be evaluated on:

  • claim breadth (composition, release profile, and manufacturing)
  • enforceability risk (prior art and obviousness exposure)
  • likelihood of Paragraph IV challenges by multiple generic sponsors
  • availability of plausible design-around formulations (different delayed-release mechanisms)

Featured-snippet answer

  • Strong estates typically show: multiple independent claim types (composition + method-of-use + manufacturing) and multi-family coverage across the delayed-release unit.

Investment implication

  • If TAUVID’s coverage is thin or heavily formulation-dependent, a faster “work-alike” substitution could compress price even before full generic ANDA entry.

What generic entry risks exist for TAUVID (ANDA, 505(b)(2), Paragraph IV challenges)?

Generic risk is driven by:

  • Orange Book “listed drug” status
  • existence and number of Orange Book patents
  • patent expiration dates and the number of likely Paragraph IV candidates

Featured-snippet answer

  • ANDA or 505(b)(2) challenge risk becomes concrete only when Orange Book lists TAUVID patents with dates and whether there have been prior Paragraph IV filings tied to this product.

Investment implication

  • For rare disease products, a single early challenge can trigger settlements and affect contract payer dynamics even if the first generic launch is delayed.

What formulation patents protect TAUVID’s delayed-release technology, and how might competitors design around?

Delayed-release products typically generate:

  • release kinetics patents (target dissolution profile)
  • polymer or matrix composition claims
  • excipient system and manufacturing process claims

Competitor design-around vectors

  • alternate polymers/matrices achieving similar delayed-release
  • modified tablet geometry or coat thickness
  • different manufacturing steps to avoid process claim overlap
  • different salt form or intermediate purification route (if claimed)

Investment implication

  • A product whose delayed-release protection is limited to a narrow excipient or process step is more vulnerable to “functional equivalence” work-arounds than a product with broad release-profile claim language.

What method-of-use patents cover TAUVID (LEMS, dosing, and patient selection)?

If method-of-use patents exist and are listed in Orange Book, they can block:

  • ANDA entry even after formulation differences
  • certain label-covering indications
  • dosing schedules if claimed

Featured-snippet answer

  • Method claims matter most if they map directly to the LEMS dosing and patient-response language in TAUVID’s label.

Investment implication

  • Method-of-use coverage can sustain brand economics by restricting generic “label carve-outs.”

What patent litigation affects TAUVID (lawsuits, settlements, and injunctions)?

Patent litigation is a valuation driver for IP-dependent rare disease assets, especially when settlements define launch dates and permissible product design.

Featured-snippet answer

  • Investment-grade litigation analysis requires:
    • case captions (district court)
    • defendants (generic sponsor names)
    • asserted patents (Orange Book numbers)
    • filing dates and settlement terms

Investment implication

  • Without confirmed litigation docket data, TAUVID’s generic forecast cannot be anchored to real-world Paragraph IV or settlement behavior.

What is TAUVID’s commercial footprint (revenue base, growth drivers, payer mix, and channel economics)?

A fundamentals-driven investment scenario depends on:

  • TAUVID annual net sales and trend
  • gross-to-net (rebates, discounts, patient assistance)
  • payer mix across Medicare, Medicaid, commercial
  • distribution footprint and contracting maturity

Featured-snippet answer

  • For TAUVID, the key commercial question is whether LEMS demand converts into durable prescribing with stable net pricing after contracting cycles.

Investment implication

  • In orphan indications, limited prescriber population increases churn risk if access barriers rise or if alternate agents gain reimbursement momentum.

How does TAUVID compare with other LEMS therapies (efficacy, safety, dosing, and market positioning)?

TAUVID competes in practice on:

  • symptomatic improvement for LEMS
  • tolerability and real-world adherence
  • oral dosing experience for delayed-release regimen

Investment implication

  • If payers treat symptomatic agents as interchangeable and negotiation leverage rests with plan formularies, TAUVID’s pricing power depends on demonstrated benefit-per-claim and tolerability advantages.

What is the competitive landscape for delayed-release amifampridine in LEMS?

Competition can come from:

  • alternative symptomatic therapies
  • next-generation delivery forms aiming at similar pharmacology with different safety or convenience
  • generic entry if IP barriers fail

Featured-snippet answer

  • TAUVID’s competitive edge is sustained by exclusivity and by label or formulary placement that is difficult to displace quickly.

What investment scenario (base case, downside, upside) fits TAUVID given IP and regulatory risks?

A credible three-scenario model must map to:

  • a launch or substitution date (generic/work-alike entry)
  • expected price erosion curve
  • volume retention assumptions based on formulary inertia
  • costs (manufacturing scale-up, contracting, and pharmacovigilance)

Featured-snippet answer

  • Base case assumes:
    • sustained market access and stable net pricing
    • no credible alternative delayed-release competitor enters before key IP dates
  • Downside assumes:
    • earlier-than-expected market entry via generic or work-alike
    • payer preference shifts due to contracting pressure and perceived interchangeability
  • Upside assumes:
    • additional label support or broader payer acceptance strengthens long-term volume
    • litigation outcomes preserve exclusivity longer than consensus

Investment implication

  • Without Orange Book patent numbers and FDA exclusivity details for TAUVID, the scenario cannot be date-calibrated. That prevents defensible probability-weighted valuation and IRR computation.

Key Takeaways

  • TAUVID’s value proposition relies on a rare-disease franchise model: durable access and IP protection.
  • The critical investment inputs are Orange Book patent coverage, exclusivity determinations, and any Paragraph IV or litigation history tied to TAUVID’s delayed-release amifampridine product.
  • Commercial fundamentals must be evaluated through net pricing durability, payer mix, and volume retention given the small LEMS prescriber pool.
  • Without Orange Book and litigation identifiers, date-based risk modeling for generic or work-alike entry cannot be completed to an actionable standard.

FAQs

  1. Is TAUVID listed in the FDA Orange Book, and which patents cover the delayed-release formulation?
  2. Have any Paragraph IV ANDA filings been made against TAUVID, and which Orange Book patents were asserted?
  3. What exclusivity periods apply to TAUVID in the US for the LEMS indication?
  4. What design-around strategies could competitors use to reach a delayed-release amifampridine product without infringing TAUVID formulation patents?
  5. How should investors model price erosion and volume loss for a rare-disease oral symptomatic therapy once exclusivity ends?

References

  1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database accessed 2026-07-30).
  2. FDA. Drug Approval Reports and Labeling for TAUVID (amifampridine delayed-release). (Accessed 2026-07-30).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.